Selected publications that use Liberum technologies, use proteins produced by Liberum, or include Liberum researchers, together with independent coverage of the company and its technology.
Expression is only useful when the protein can answer a biological question.
We develop our systems with experimental relevance in mind, from nanobody diagnostics and distributed biomanufacturing to functional signalling studies.
A study of glycoRNA and heparan sulfate biology published in Nature.
Liberum use: the Nature methods explicitly identify cell-free E. coli protein production by Liberum Biotech for the VEGF-A165-HS wild-type and R/K proteoforms used in functional signalling experiments.
Read publication →A ten-site demonstration of distributed cell-free biomanufacturing for research, diagnostics, vaccines and other bioproducts.
Liberum connection: the study used Liberum Juice alongside other cell-free systems, and includes Liberum researchers among the authors.
Read publication →RAMONA, a modular nanobody-based antigen detection platform designed for rapid adaptation and point-of-need use.
Liberum use: nanobody constructs were expressed from linear DNA in Liberum Juice cell-free lysate using a Liberum cell-free optimized backbone.
Read publication →MANGO, an automated benchtop system for cell-free protein synthesis and purification at the point of use.
Liberum connection: Liberum researchers are coauthors on the work, which demonstrates automated production of nanobodies, cloning enzymes and diagnostic enzymes.
Read publication →Selected independent coverage of Liberum and the technology we are building.
CEPI highlighted a £2.16 million proof-of-concept program led by CPI to develop the MANGO platform for automated, cell-free production of virus-like particle vaccines.
Liberum connection: CEPI names Liberum Biotech as a consortium partner working with CPI, Imperial College London, University of Leeds, University of Toronto, University of Waterloo and FioCruz on the rapid-response vaccine manufacturing platform.
Read CEPI →Nature highlighted emerging approaches to producing proteins outside living cells and referenced Liberum among companies developing cell-free protein synthesis technology.
Read Nature →IndieBio featured Liberum's cell-free protein printing technology in a discussion of on-demand biologics manufacturing, describing genetic material being added directly to enzymatic systems to produce proteins in hours.
The article positions cell-free protein printing as part of a broader shift toward flexible, localized and on-demand drug manufacturing.
Read IndieBio →BetaKit covered Liberum's seed financing and its effort to compress recombinant protein production from conventional multi-week workflows toward much faster cell-free production.
The article described Liberum's ambition as broader than a single cell-free product, positioning the company around protein synthesis infrastructure.
Read BetaKit →TechCrunch profiled Liberum as part of IndieBio's Demo Day cohort, highlighting the company's approach to recombinant protein production.
TechCrunch described Liberum's early vision as a protein printer capable of reducing custom recombinant protein production from weeks to hours.
Read TechCrunch →For antibody fragments and cell-free reagents, visit cell-free.com. For rapid full-length IgG production, visit Fynd. For affinity maturation, vaccine antigens or custom cell-free work, talk to us directly.
Tell us what you are trying to express, evolve or manufacture.